Orthocell Ltd ( (AU:OCC) ) just unveiled an announcement.
Orthocell Limited announced that its CEO, Paul Anderson, will present at the HealthInvest 2025 conference in Sydney, highlighting the company’s progress and strategic initiatives. The presentation will include an update on the US FDA application for the Remplir nerve repair product, which signifies a critical step in Orthocell’s expansion efforts and could enhance its market positioning in regenerative medicine.
More about Orthocell Ltd
Orthocell Limited is a regenerative medicine company focused on developing products for the repair of bone and soft tissue injuries. Their portfolio includes collagen medical devices for dental and orthopedic applications, such as Striate+™ and Remplir™, as well as autologous cell therapies aimed at regenerating damaged tendon and cartilage tissue. The company is actively working on expanding its tendon cell therapy in the US market.
YTD Price Performance: 9.93%
Average Trading Volume: 1,589,294
Technical Sentiment Signal: Sell
Current Market Cap: A$361.8M
For a thorough assessment of OCC stock, go to TipRanks’ Stock Analysis page.